Arcellx

Associate Director, Regional Marketing & Thought Leader Liaison

Redwood City, California, United States

Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

A Bachelor's degree is required, with an advanced degree (PharmD, PhD, MBA) being preferred. Candidates should possess 8+ years of experience in the biopharmaceutical industry, including at least 3-5 years in hematology/oncology, and prior experience in field marketing, key customer marketing, or thought leader liaison roles is highly desirable. Experience in multiple myeloma or CAR T is strongly preferred, along with a demonstrated ability to engage credibly and compliantly with academic and community thought leaders and strong collaboration skills for matrixed environments.

Responsibilities

The Associate Director will identify, engage, and maintain relationships with thought leaders and key customers in the multiple myeloma and CAR T space. This role involves supporting regional advisory boards, executive encounters, and educational initiatives, while collaborating with cross-functional partners to ensure cohesive external engagement. Responsibilities include capturing and synthesizing field insights to inform brand planning, promotional messaging, and HCP education efforts, assisting with the development of a national and regional thought leader map, and providing key input into the planning and execution of medical and commercial congress activity. The role also contributes to the creation of compliant, value-added customer engagement tools and resources.

Skills

Marketing Strategy
Thought Leader Engagement
Customer Engagement
CAR T
Biotechnology
Oncology
Multiple Myeloma
Field Marketing
Commercial Strategy

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters
2014Year Founded
$194.5MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Work Hours
401(k) Company Match
Fully-Paid Parental Leave
Tuition Reimbursement
Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.
Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.
Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.
The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.
ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.
Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.
Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI